Suppr超能文献

系统性轻链淀粉样变患者的心脏反应分级标准。

Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.

机构信息

Division of Hematology, Mayo Clinic, Rochester, MN.

National Amyloidosis Centre, University College London, Royal Free Hospital Campus, London, United Kingdom.

出版信息

J Clin Oncol. 2023 Mar 1;41(7):1393-1403. doi: 10.1200/JCO.22.00643. Epub 2022 Oct 10.

Abstract

PURPOSE

Binary cardiac response assessment using cardiac biomarkers is prognostic in light chain amyloidosis. Previous studies suggested four-level cardiac responses using N-terminal prohormone of brain natiuretic peptide improves prognostic prediction. This study was designed to validate graded cardiac response criteria using N-terminal prohormone of brain natiuretic peptide/brain natiuretic peptide.

PATIENTS AND METHODS

This retrospective, multicenter study included patients with light chain amyloidosis who achieved at least a hematologic partial response (PR) and were evaluable for cardiac response. Four response criteria were tested on the basis of natriuretic peptide response depth: cardiac complete response (CarCR), cardiac very good partial response (CarVGPR), cardiac PR (CarPR), and cardiac no response (CarNR). Response was classified as best response and at fixed time points (6, 12, and 24 months from therapy initiation). The study primary outcome was overall survival.

RESULTS

651 patients were included. Best CarCR, CarVGPR, CarPR, and CarNR were achieved in 16%, 26.4%, 22.9%, and 34.7% of patients, respectively. Patients in cardiac stage II were more likely to achieve CarCR than patients in cardiac stage IIIA and IIIB (22% 13.5% 3.2%; < .001). A deeper cardiac response was associated with a longer survival (5-year overall survival 93%, 79%, 65%, and 33% for CarCR, CarVGPR, CarPR, and CarNR, respectively; < .001). Fixed time-point analyses and time-varying covariates Cox regression analysis, to minimize survivorship bias, affirmed the independent survival advantage of deeper cardiac responses. Four-level response performed better than two-level response as early as 12 months from therapy initiation.

CONCLUSION

Graded cardiac response criteria allow better assessment of cardiac improvement compared with the traditional binary response system. The study re-emphasizes the importance of early diagnosis, which increases the likelihood of deep cardiac responses.

摘要

目的

使用心脏生物标志物对心脏进行二元反应评估在轻链淀粉样变性中具有预后价值。先前的研究表明,使用脑钠肽前体(NT-proBNP)的四级心脏反应可提高预后预测能力。本研究旨在使用 NT-proBNP/脑钠肽验证分级心脏反应标准。

患者和方法

本回顾性、多中心研究纳入了至少达到血液学部分缓解(PR)且可评估心脏反应的轻链淀粉样变性患者。基于利钠肽反应深度,测试了四种反应标准:心脏完全缓解(CarCR)、心脏很好的部分缓解(CarVGPR)、心脏 PR(CarPR)和心脏无反应(CarNR)。反应按最佳反应和固定时间点(从治疗开始后 6、12 和 24 个月)进行分类。该研究的主要终点是总生存。

结果

共纳入 651 例患者。最佳 CarCR、CarVGPR、CarPR 和 CarNR 的患者比例分别为 16%、26.4%、22.9%和 34.7%。心脏分期为 II 期的患者比 IIIA 期和 IIIB 期的患者更有可能达到 CarCR(22% 13.5% 3.2%;<.001)。更深的心脏反应与更长的生存时间相关(5 年总生存率分别为 93%、79%、65%和 33%,CarCR、CarVGPR、CarPR 和 CarNR;<.001)。固定时间点分析和时变协变量 Cox 回归分析,以最小化生存偏差,证实了更深的心脏反应具有独立的生存优势。从治疗开始后 12 个月开始,四级反应比二级反应更早地表现出更好的预后。

结论

与传统的二元反应系统相比,分级心脏反应标准可以更好地评估心脏改善情况。该研究再次强调了早期诊断的重要性,这增加了达到深度心脏反应的可能性。

相似文献

1
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
J Clin Oncol. 2023 Mar 1;41(7):1393-1403. doi: 10.1200/JCO.22.00643. Epub 2022 Oct 10.
3
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.
JAMA Oncol. 2024 Oct 1;10(10):1362-1369. doi: 10.1001/jamaoncol.2024.2629.
5
Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Hematol Oncol. 2023 Oct;41(4):725-732. doi: 10.1002/hon.3135. Epub 2023 Mar 27.
7
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.
Eur Heart J. 2022 Dec 1;43(45):4722-4735. doi: 10.1093/eurheartj/ehac363.
8
Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e769-e776. doi: 10.1016/j.clml.2020.05.025. Epub 2020 Jun 7.
9
Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.
Haematologica. 2020 May;105(5):1405-1413. doi: 10.3324/haematol.2019.217695. Epub 2019 Aug 8.

引用本文的文献

1
Monoclonal gammopathy progressing to systemic amyloidosis with cardiac involvement. A case report.
Arch Peru Cardiol Cir Cardiovasc. 2025 Jun 27;6(2):104-109. doi: 10.47487/apcyccv.v6i2.477. eCollection 2025 Apr-May.
2
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis.
Blood Neoplasia. 2025 Mar 10;2(2):100092. doi: 10.1016/j.bneo.2025.100092. eCollection 2025 May.
6
Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosis.
Br J Haematol. 2025 Apr;206(4):1141-1148. doi: 10.1111/bjh.20021. Epub 2025 Feb 21.
7
Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response.
JACC Asia. 2024 Nov 26;5(1):74-84. doi: 10.1016/j.jacasi.2024.10.005. eCollection 2025 Jan.
8
Current landscape of clinical management for systemic light chain amyloidosis.
Future Cardiol. 2025 Mar;21(4):203-205. doi: 10.1080/14796678.2025.2460392. Epub 2025 Jan 31.
9
Advancements in Cardiac Amyloidosis Treatment.
Biomedicines. 2024 Dec 31;13(1):79. doi: 10.3390/biomedicines13010079.
10
Ethnicity in systemic AL amyloidosis may impact risk stratification.
Haematologica. 2025 May 1;110(5):1202-1206. doi: 10.3324/haematol.2024.286746. Epub 2025 Jan 16.

本文引用的文献

3
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis.
Amyloid. 2021 Mar;28(1):1-2. doi: 10.1080/13506129.2020.1868810. Epub 2021 Jan 7.
4
Next generation flow cytometry for MRD detection in patients with AL amyloidosis.
Amyloid. 2021 Mar;28(1):19-23. doi: 10.1080/13506129.2020.1802713. Epub 2020 Aug 12.
5
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
J Clin Oncol. 2020 Oct 1;38(28):3252-3260. doi: 10.1200/JCO.20.01285. Epub 2020 Jul 30.
6
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.
JAMA. 2020 Jul 7;324(1):79-89. doi: 10.1001/jama.2020.5493.
7
Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.
Blood Adv. 2020 Mar 10;4(5):880-884. doi: 10.1182/bloodadvances.2019001331.
9
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.
Am J Hematol. 2020 May;95(5):497-502. doi: 10.1002/ajh.25746. Epub 2020 Feb 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验